Topiramate Capsule, Coated Pellets
Product Images NDC 68462-219

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68462-219). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

This is a table showing the cumulative rates for the time to the first seizure for two groups: one group taking Topiramate 50 mg/day (N=234) and the other group taking Topiramate 400 mg/day (N=236). The chart displays time in days on the x-axis and the cumulative rates on the y-axis. This data can be used to compare the effectiveness of the two different doses of Topiramate in preventing seizures over time.*

FDA Label Image

Figure2 (Figure2)

This text provides data on the change from baseline to the double-blind phase in average monthly migraine period rate for different doses of placebo and topiramate. The study includes three different groups with varying doses of topiramate (100 mg/day and 200 mg/day) and a placebo group. The numbers of participants in each group are also mentioned. The results indicate statistically significant differences between the groups, as denoted by the p-values provided.*

FDA Label Image

Structure (Image 01)

FDA Label Image

Label15mg (Label15mg)

FDA Label Image

Label25mg (Label25mg)

FDA Label Image

Logo (Logo)

FDA Label Image

Logo2 (Logo2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.